11th March 2026
Professor Michelle Lockley and Dr Oliver Pearce have both been awarded prestigious Programme Foundation Awards from Cancer Research UK, worth nearly £1.5 million each, to support the work of their research groups at Barts Cancer Institute, Queen Mary University of London.
Read more12th February 2026
Thousands of people with advanced bladder cancer across the UK will now receive three rather than six chemotherapy cycles after Queen Mary University of London-led research led to a change to NHS treatment guidelines. For patients, this means fewer toxic side effects and a better quality of life during treatment.
Read more21st August 2025
The new combination treatment offers hope to thousands of people living with advanced urothelial cancer. The clinical trials, led by Professor Tom Powles at Barts Cancer Institute, Queen Mary University of London, showed that overall survival rates were almost twice as long with this new treatment compared to the current standard treatment.
Read more11th August 2025
Researchers at Barts Cancer Institute (BCI), Queen Mary University of London, will play a part in a revolutionary new partnership with King’s College London and the University of Leeds, aiming to accelerate and optimise the clinical translation of healthcare nanotechnologies.
Read more22nd May 2025
A new strategy to help powerful cancer-targeting immune cells, known as CAR-T cells, infiltrate pancreatic tumours has been developed by researchers at Barts Cancer Institute, Queen Mary University of London. The unique three-pronged approach could pave the way for making CAR-T cell therapy—a treatment that has transformed care for certain blood cancers—effective against pancreatic cancer, a disease that remains very difficult to treat.
Read more17th October 2024
Researchers at Barts Cancer Institute reveal promising acute myeloid leukaemia treatment targeting fat metabolism, addressing the urgent need for better therapies.
Read more